GlassScriptPhysician profile
Alicia A Noto
NPI 1265605505
$2,670.80
in general payments reported to CMS, 2019-2025
25 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $194 · 2023: $847 · 2024: $931 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,919.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $500.92 | 2023-2025 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $405.18 | 2021-2025 | Verquvo, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $381.25 | 2021-2024 | Farxiga, Lokelma |
| Abbott Laboratories | $208.97 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $172.63 | 2023-2025 | Lifevest |
| Daiichi Sankyo INC. | $153.35 | 2023-2024 | Injectafer |
| Janssen Pharmaceuticals, INC | $149.27 | 2021 | |
| Glaxosmithkline, LLC. | $125.00 | 2024 | Arexvy |
| Pfizer INC. | $103.53 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.39 | 2022-2023 | Jardiance |
| Scpharmaceuticals INC. | $43.59 | 2023-2024 | |
| Atricure, INC. | $41.58 | 2024 | |
| Amgen INC. | $41.15 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $38.38 | 2023-2024 | Camzyos, Eliquis |
| Tactile Systems Technology INC | $33.92 | 2023-2024 | Flexitouch Plus, Entre Plus |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $30.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $29.38 | 2023 | |
| Alnylam Pharmaceuticals INC. | $28.58 | 2024 | Amvuttra |
| Novo Nordisk INC | $24.13 | 2024 | Wegovy |
| Lantheus Medical Imaging, INC. | $23.08 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $20.82 | 2023 | Inpefa |
| Amarin Pharma, INC. | $18.73 | 2022 | |
| Esperion Therapeutics, INC. | $17.89 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $16.68 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.19 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Noto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.